Desentum is preparing to start clinical trials with birch pollen allergy vaccine

Desentum is preparing to start clinical trials with birch pollen allergy vaccine

News

The birch pollen hypoallergen has shown promise in laboratory tests. Next, it needs to be evaluated in clinical trials.

"The goal is to initiate the first clinical study in the first quarter of 2018. It will be a small study resembling a standard skin prick allergy test. Our laboratory tests support the hypothesis on which the hypoallergen design is based. The goal of the clinical study is to investigate human response to a small amount of the hypoallergen." says Pekka Mattila, CEO of Desentum.
 

Read the entire article here.


Related posts